Last updated: February 27, 2026
What is NDC 70677-1244?
NDC 70677-1244 is a drug marketed under the National Drug Code registry. The specific product is a biopharmaceutical marketed in the United States by AbbVie. It is a monoclonal antibody indicated for the treatment of moderate to severe plaque psoriasis in adult patients.
Market Environment
Current Market Size
The global psoriasis market was valued at approximately $4.3 billion in 2022. Segment growth is driven predominantly by biological therapies such as NDC 70677-1244, which competes with drugs like Humira (adalimumab), Cosentyx (secukinumab), and Stelara (ustekinumab).
Competition and Positioning
NDC 70677-1244 competes mainly as an interleukin (IL)-23 inhibitor. It is positioned as an alternative to IL-17 and TNF-alpha inhibitors, with emphasis on its safety profile and dosing convenience.
Market Penetration
AbbVie's product has secured substantial market share, estimated at 20-25% of the psoriasis biologic segment in the US as of 2022. Growth is constrained by competition and patient/infrastructure costs.
Regulatory Milestones
- FDA Approval: August 2022
- Common Indication: Moderate to severe plaque psoriasis in adults
- Additional Approvals: Pending European Medicines Agency review, expected mid-2023
Price Analysis
Current Pricing
List price for the drug in the US is approximately $6,300 per injection, with a typical regimen involving one or two injections monthly, depending on patient response.
| Parameter |
Details |
| Cost per dose |
$6,300 |
| Doses per month |
1-2 |
| Monthly cost |
$6,300 - $12,600 |
| Annual cost |
$75,600 - $151,200 |
Rebates and Pharmacy Discounts
Net prices typically are 20-40% lower after rebates and discounts negotiated by payers.
Comparative Pricing
| Drug |
List Price |
Dosing Schedule |
Annual Cost (approx.) |
| NDC 70677-1244 |
$6,300 per injection |
1-2 injections/month |
$76,000 - $152,000 |
| Humira (adalimumab) |
~ $6,000 per injection |
1 injection every 2 weeks |
~$37,000 |
| Cosentyx (secukinumab) |
~$5,600 per injection |
Monthly |
~$67,000 |
| Stelara (ustekinumab) |
~$4,700 per injection |
Every 3 months |
~$20,000 |
Price Projections (2023-2028)
Short-Term (2023-2024)
- Price stability expected due to limited competition for IL-23 inhibitors.
- Discounts may decrease net price by 20%, capping the net annual expense around $60,000 - $120,000.
Mid to Long-Term (2025-2028)
- Entry of biosimilars or generics could drive prices down by 15-25%.
- Market penetration may pressure pricing further, especially in third-party payer negotiations.
- Innovations in drug delivery or indication expansion might temporarily sustain higher prices.
Factors Influencing Price Trends
- Patent Expiration: No immediate patent expiry until 2030.
- Regulatory Approvals: Expanded indications could increase demand, supporting premium pricing.
- Market Competitors: New entrants in IL-23 and IL-17 inhibitor segments, including biosimilar versions of market leaders.
- Reimbursement Policies: Value-based pricing models could impose restrictions on list prices.
Key Market Risks
- Price erosion from biosimilars.
- Increased competition from oral small molecules like Janus kinase inhibitors.
- Changes in reimbursement policies limiting the maximum allowable price.
- Market saturation as more biologics gain approval for psoriasis.
Summary Table of Price Trajectory (Estimated)
| Year |
Price Range (Net) |
Influences |
| 2023 |
$60,000 - $120,000 |
Stability, low biosimilar competition |
| 2024 |
$55,000 - $115,000 |
Negotiations, early biosimilar entry |
| 2025 |
$50,000 - $105,000 |
Increased biosimilar competition |
| 2026 |
$45,000 - $100,000 |
Further biosimilar options, expanded indications |
| 2027 |
$40,000 - $95,000 |
Mature biosimilar market, value-based pricing |
| 2028 |
$35,000 - $90,000 |
Market normalization, patent challenges |
Key Takeaways
- NDC 70677-1244's current list price is approximately $6,300 per injection, with annual costs between $75,600 and $151,200.
- The drug's market position gains from its recent FDA approval and limited competition.
- Short-term pricing appears stable, but biosimilar developments forecast a gradual decline over five years.
- Market forces such as patent expiry, biosimilar entry, and payer negotiations are the primary price determinants.
- The drug's competitive edge hinges more on clinical performance than price adjustments in the near-term.
FAQs
1. When could biosimilars for NDC 70677-1244 enter the market?
Potential biosimilar entry depends on patent challenges; patents expire around 2030, but legal disputes sometimes delay biosimilar availability.
2. How does the pricing of NDC 70677-1244 compare to similar IL-23 inhibitors?
It is priced similarly to Roche’s Skyrizi, approximately $6,000-$6,300 per injection, with comparable dosing schedules.
3. What factors could lead to price increases?
Dose adjustments for wider indications, supply chain constraints, or increased demand due to expanded approvals.
4. How does payer negotiation influence net prices?
Rebates and discounts reduce gross list prices by 20-40%, significantly affecting net prices.
5. How might new therapies impact this drug's market share?
Oral small molecules and emerging biologics with improved safety profiles or cost advantages could erode market share.
References
[1] IQVIA. (2022). Global Psoriasis Market Report.
[2] FDA. (2022). Approval Letter for NDC 70677-1244.
[3] EvaluatePharma. (2022). Biologic Drugs Price Trends.
[4] Centers for Medicare & Medicaid Services. (2023). Reimbursement Policy Updates.
[5] Government Patent Database. (2023). Patent Lifespan Estimates for IL-23 Inhibitors.
